Noor Ul Ain Rehman
Thu, February 12, 2026 astatine 5:54 AM CST 2 min read
The firm’s valuation enactment is based connected a discounted currency travel model, yielding an endeavor worth of astir $34 cardinal and supporting a 12‑month terms people of $40 per share, which is underpinned by an 8% discount complaint and 4% terminal maturation rate. The assumptions constituent towards H.C. Wainwright’s assurance successful the ivonescimab information acceptable and the well‑validated quality of PD‑1 arsenic a target.
The standing update came aft Summit Therapeutics Inc. (NASDAQ:SMMT) announced connected January 29 that the FDA accepted for filing the company’s Biologics License Application seeking support for ivonescimab successful operation with chemotherapy successful patients with epidermal maturation origin receptor-mutated locally precocious oregon metastatic non-squamous non-small compartment lung crab post-tyrosine kinase inhibitor therapy. Management reported that the FDA provided a Prescription Drug User Fee Act extremity enactment day of November 14, 2026.
Summit Therapeutics Inc. (NASDAQ:SMMT) is simply a biopharmaceutical institution that specializes successful creating caller medications for infectious and cancerous diseases.
While we admit the imaginable of SMMT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This nonfiction is primitively published at Insider Monkey.

1 month ago
22




English (CA) ·
English (US) ·
Spanish (MX) ·